Genoptix, Inc. to Announce Third Quarter 2008 Financial Results

CARLSBAD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Genoptix, Inc.
(Nasdaq: GXDX), a provider of personalized diagnostic services, announced
today that it expects to report its financial results for the third quarter
after closing of the NASDAQ Global Market on Thursday, November 6, 2008.
A conference call hosted by President and CEO, Dr. Tina S. Nova, and other
members of senior management will take place on the same day at 2:00pm PST
(5:00pm EST) and will be webcast live on the Genoptix website.
To access the live conference call via phone, dial 800-561-2693 in the
U.S. or Canada and 617-614-3523 for international callers. Please specify to
the operator that you would like to join the "Genoptix Third Quarter 2008
Earnings Conference Call." The participant code for the call is 61140638. If
you are unable to listen to the live webcast, a replay of the call will be
available through Thursday, November 13, 2008. Interested parties can access
the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally
and entering the reservation number 60056810.
The conference call will be webcast live on the Internet and is accessible
through the investor relations section of the Genoptix website at
http://www.genoptix.com, or by accessing the external website,
http://www.fulldisclosure.com. To participate in the webcast, please connect
to the Genoptix website several minutes prior to the start time to register,
download and install any necessary software that may be required. An online
replay is planned to follow shortly after and will be available until Friday,
December 5, 2008.
About Genoptix, Inc.
Founded in 1999, Genoptix has been profitable since the first quarter of
2007 and completed its initial public offering in November 2007. Genoptix is
a specialized laboratory service provider focused on delivering personalized
and comprehensive diagnostic services to community-based hematologists and
oncologists. Genoptix' highly trained group of hematopathologists utilizes
sophisticated technology to provide integrated testing and actionable
diagnostic reports. Its diagnostic services are designed to optimize the care
of patients suffering from hematomalignancies, or cancers of the blood and
bone marrow, including leukemia and lymphoma.
Any statements in this press release or that may be made on the Genoptix
conference call about expectations, beliefs, plans, objectives, assumptions or
future events, or future performance are not historical facts and are
forward-looking statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks, uncertainties and
assumptions that may cause actual results, levels of activity, performance or
achievements to differ materially from those expressed or implied by any
forward-looking statement. For information about risks and uncertainties that
Genoptix faces, please refer to the "Risk Factors" section in the Company's
most recent Quarterly Report on Form 10-Q, as well as its Annual Report on
Form 10-K for the year ended December 31, 2007 filed with the Securities and
Exchange Commission on February 12, 2008. Genoptix assumes no obligation and
expressly disclaims any duty to update any forward-looking statement to
reflect events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events.
SOURCE Genoptix, Inc.

Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc.,
+1-760-930-7150, investorrelations@genoptix.com; or Joleen Schultz, Principal
of Mentus, +1-858-455-5500, ext. 215, jschultz@mentus.com, for Genoptix, Inc.